30 Years After Transition, Cori Cohn Speaks Out (#32)
25 August 2025
With Cori Cohn
North America
Cori Cohn transitioned medically at nineteen in 1994, before clinical protocols or long-term outcome data existed. Thirty years later, his account of surgical consequences and lasting regret illustrates the very evidence gap that has prompted countries across northern Europe — including Sweden, Finland, Denmark and the United Kingdom — to restrict or pause youth gender medicine. His testimony gives human texture to the questions that systematic reviews have repeatedly raised: whether adolescents can meaningfully consent to irreversible interventions, and what durable harm looks like when longitudinal follow-up has been absent.
Cori Cohn was nineteen years old and living in Reno, Nevada, when he underwent genital surgery in 1994 — before gender clinics were widespread, before systematic evidence of long-term outcomes existed, and before any European regulatory body had examined the question. He began taking oestrogen at eighteen after encountering the concept of transsexualism through television. His route to surgery involved consulting multiple psychologists until a third approved the procedure, a process he describes as doctor shopping. There was no clinical framework in place that would today be considered rigorous gatekeeping. Three decades later, Cohn describes living in a state he calls "subhuman" — neither male nor female — and speaks candidly about how surgical injury has permanently impaired his capacity for intimacy and his ability to sustain relationships. These are not incidental biographical details. They are precisely the kind of long-term patient-reported outcomes that systematic reviews across Europe have consistently identified as missing from the published evidence base on gender medicine. The Cass Review, published in April 2024 and commissioned by NHS England, found that the evidence base for puberty blocker and hormone prescribing in adolescents was of remarkably low quality: studies were too small, too short in follow-up, and insufficiently designed to support conclusions about long-term wellbeing. Swedish health authorities issued national guidelines in 2022 restricting hormonal treatment for minors to exceptional cases. Finland's Council for Choices in Health Care moved in the same direction in 2020. Denmark followed in 2024. Cohn's experience predates all of these reviews, and illustrates what happens when intervention proceeds without longitudinal outcome data. What distinguishes his testimony is its duration. Most documented accounts of regret and detransition cover shorter timescales. Cohn's thirty-year arc encompasses adolescent distress — he describes being a sensitive boy who was bullied and alienated from male peers — through medical intervention and into the long-term consequences that followed. The systematic reviews shaping European policy have called repeatedly for exactly this kind of extended follow-up. Personal testimony cannot substitute for research, but it can illuminate in human terms what the absence of that research costs. Since 2022 Cohn has testified before state legislatures across the United States in support of laws restricting paediatric gender medicine, framing his motivation as protection for young people from an intervention he believes he was not equipped to consent to at nineteen. The question of meaningful informed consent for irreversible procedures has also been central to European jurisprudence. The UK High Court's 2020 Bell v Tavistock judgment engaged directly with whether adolescents could adequately understand consequences including permanent infertility — a judgment subsequently reversed by the Court of Appeal, though the underlying questions remain live across European jurisdictions. His account does not constitute clinical evidence. But it raises, through thirty years of lived experience, exactly the questions that have driven policy revision across northern Europe: what are the durable outcomes of early medical transition, and what obligation falls on clinical systems when long-term evidence is absent?
